Byoung-Yong Shim

11PUBLICATIONS
105CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Feb 06, 2026
Author Correction: DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B.

Keun-Wook Lee, Devalingam Mahalingam, Byoung Yong Shim

|Feb 06, 2026
JIN-A02, a Mutant-Selective Fourth-Generation EGFR Inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLC.

Eun Ji Lee, Ji Ae Ko, Min-Je Kim

|Sep 09, 2025
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B).

James Chih-Hsin Yang, Mengzhao Wang, Ludovic Doucet

|Jul 10, 2025
DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B.

Keun-Wook Lee, Devalingam Mahalingam, Byoung Yong Shim

|May 31, 2025
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial.

Tina Cascone, Laura Bonanno, Florian Guisier

|Sep 28, 2024
Common Cancer-Related Factors and the Risk of Developing Kaposi Sarcoma in Individuals without AIDS: Korea National Health Insurance Services Claims Database.

Ji Eun Shin, Kyungdo Han, Ho Jung An

Pageof 2

Frequent Collaborators

3 joint publications

Samuel J Klempner

3 joint publications

Ji-Youn Han

2 joint publications

Hyung Soon Park

2 joint publications

Cynthia A Sirard